Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Big time revenue news this week, once more people get wind of that as well as the tiny float we could see $1+ IMO
$USAQ Next week should get real interesting here.. buy the dip!
USA Equities Corp. Reports Fourth Quarter and Full Year 2021 Financial Results
Press Release | 04/05/2022
Fourth Quarter 2021 Revenue Up 265%
? Revenue Surpassed $1.4 million for the year ended 2021 Compared to $124,000 for 2020
? Gross Margin of 52% in Q4 Increased 1,200 Basis Points Versus Q4 2020
? Strong balance sheet growth during 2021 with $2.2M in assets including the AllergiEnd® asset acquisition
? Pending FINRA approval to change the Company’s Name to QHSLab, Inc.
West Palm Beach, FL, April 05, 2022 (GLOBE NEWSWIRE) -- USA Equities Corp (OTCQB: USAQ), a digital healthcare company focused on providing clinicians with artificial intelligence tools to leverage proactive, value-based healthcare solutions through the use of emerging digital and point of care technologies, announced its financial results for the fourth quarter and full-year 2021.
$USAQ .55 continues to clear..nice volume day for this one..
$USAQ Strong buy opportunity @barchart
You sure $USAQ Is not a Nasdaq stock? Because with quarter and year end report..sure as hell acts like one..nice find..just saw the year end report trending..
$USAQ Revenue Surpassed $1.4 million for the year ended 2021 Compared to $124,000 for 2020
Absolutely beautiful numbers from last year. Should be a good quarterly when it comes out to in my opinion.
going to bid fish for some here, maybe get lucky
$USAQ Fourth Quarter 2021 Revenue Up 265% https://bullish.link/CKQ0g
Just found $USAQ on Twitter, and saw this news from this week, revenues +265% for Q1, with a float under $2M. Going to need to see if I can scoop some shares on the bid, love under the radar stocks
https://www.otcmarkets.com/stock/usaq/news/USA-Equities-Corp-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results?id=350961
USAQ
? Revenue Surpassed $1.4 million for the year ended 2021 Compared to $124,000 for 2020
? Gross Margin of 52% in Q4 Increased 1,200 Basis Points Versus Q4 2020
? Strong balance sheet growth during 2021 with $2.2M in assets including the AllergiEnd® asset acquisition
? Pending FINRA approval to change the Company’s Name to QHSLab, Inc.
West Palm Beach, FL, April 05, 2022 (GLOBE NEWSWIRE) -- USA Equities Corp (OTCQB: USAQ), a digital healthcare company focused on providing clinicians with artificial intelligence tools to leverage proactive, value-based healthcare solutions through the use of emerging digital and point of care technologies, announced its financial results for the fourth quarter and full-year 2021.
$USAQ 2021 Financial Results
Total assets for the year ended December 31, 2021 were $2,208,497, compared to $297,863 the same period in 2020
Total revenues for the year ended December 31, 2021 were $1,414,421, compared to $124,532 revenues in the comparable period of 2020
The Company generated a gross profit of $670,748, or a gross margin of approximately 47.4% during the year ended December 31, 2021
QHSLab, the flagship product of USA Equities Corp, has garnered tremendous brand recognition. We have decided to change the name of our Company to QHSLab, Inc. pending FINRA approval expected in April 2022.
Our Operating Model
Our mission is to enhance the quality of life of individuals and populations through physician-directed digital medicine and innovative, artificial intelligence (AI) enhanced preventive health technologies.
Value Based. The Company provides the tools that enhance health care for patients while lowering costs to insurance providers and corporate America and allowing physicians to increase their practice revenues.
Patient Centered. Our products streamline the relationship between physicians and their patients, providing a high-quality experience for patients, and increasing the value provided to them during care.
Time Saving. Physicians can maximize face-to-face office visits and non-face-to-face patient education while generating additional revenue through reimbursable preventative services.
Prevention Focused. Our products are designed to promote prevention, early detection, management, and reversal of chronic diseases.
Executing our Growth Strategy
Growing Recurring Revenue Base
Increasing the number of medical practitioners utilizing our point-of-care and digital medicine services, growing our revenue per client metric.
Future distribution channels include Management Service Organization (MSO) partnerships, Independent Physician Associations (IPA’s), and complementary digital health networks.
Expanding Product Portfolio
Additional point-of-care diagnostic, digital medicine, and treatments that PCPs can use, prescribe, and be reimbursed for under existing government and private insurance programs.
Increasing Industry Visibility
Increasing the number of company/university-sponsored medical conferences by partnering with the University of Miami to introduce and educate members of the medical community about the technology and revenue opportunities available.
USA Equities Corp. $USAQ Reports Fourth Quarter and Full Year 2021 Financial Results https://finance.yahoo.com/news/usa-equities-corp-reports-fourth-120000501.html
$USAQ Updates Investors on Significant Progress @smallcapvoice https://bit.ly/3lPQ2RS
USA Equities Corp. (OTCQB: $USAQ) is on high alert for today’s trading https://bit.ly/3BpxBtj @smallcapvoice
USA Equities Corp. $USAQ Announces Strong Second Quarter 2021 Results @smallcapvoice https://bit.ly/3jYDoix
$USAQ is on High Alert Today with News Out https://bit.ly/3lA8HCO
$USAQ Revenue Grew 50% to $456,219 Compared to Q1 2021
$USAQ News! USA Equities Corp. Announces Strong Second Quarter 2021 Financial Results @smallcapvoice https://lnkd.in/gu6VswX
$USAQ Getting noticed let's push!!
Quarterly needs to be reviewed by the Auditor and then it's go time!
Okay $USAQ I see you on Reddit! https://t.co/lfF43G0A84
— Duly Diligent Trader ♃ (@DlyDiligentTrdr) July 13, 2021
$USAQ BUY at barchart https://www.barchart.com/stocks/quotes/USAQ/overview
Solid close today!
Holding green nicely this afternoon.
USAQ
Decent dollar volume coming in here on USAQ
Bids are even bigger now..
.88's super thin now!
USAQ
Check the bids moving in..they are getting impatient to get in..
Huge volume let's break and hold $1 today
Bids are stacking..$1 test looming large here...
We are off to a good start.
USAQ
Looking good bigfoot.
USAQ
Up 21 percent now on strong volume!
$USAQ Huge buys pouring in now!
Bidders moving up early here..want in before the long weekend
USAQ's Purchase includes AllergiEnd® Method Patent, Trademark and Website
USAQ
The company has entered into a distribution agreement with a prominent physician management services organization (MSO) for its AllergiEnd® allergy diagnostic and allergen immunotherapy products and services. The MSO will facilitate the working relation between USAQ and its physician members, as well as provide marketing and advertising support. Given the size of the MSO’s member roster, the roll out will be done in stages so as to ensure adequate training and staff support.
“Today’s announcement is further evidence of our continued progress and momentum as we expand our independent medical provider practice network. The growing interest in AllergiEnd®’s allergy diagnostic services and allergen immunotherapy products reflects the attractiveness of our value-based tools to proactively address chronic disease, provide preventive care as well as enable the broad market of general practitioner physicians to broaden their practices and revenue base,” said Troy Grogan, CEO of USA Equities Corp.
USAQ
Trader's Cheet Sheet >> https://www.barchart.com/stocks/quotes/USAQ/cheat-sheet
Their objectives are to develop proprietary software tools, point of care devices and approaches, providing more granular, timely and specific clinical decision-making information for practicing physicians and other health care providers to address today’s allergy prone, obese, diabetic and cardiovascular disease population.
USAQ
"Litchfield Hills research report highlights the strong sequential improvement in revenue and gross margin we saw in our first quarter financial results. We have made significant progress over the past few months with the commercial launch of AllergiEnd®’s allergy diagnostic and Allergen immunotherapy products expansion of our management team and visibility in the industry among primary care physicians. We continue to expect an increase in revenue and gross margin in the second quarter of 2021” said Troy Grogan, CEO of USA Equities Corp.
USAQ
USA Equities Corp. (USAQ) Acquisition Strengthens USAQ Business Model and Strategic Position
Let’s close the week out strong here..
They have a good plan.
USAQ
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
864
|
Created
|
05/07/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |